Evaluation of Hemostasis in Bleeding and Thrombotic Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-10-31

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study will be to assess the coagulation system in-vitro in a variety of bleeding and clotting disorders using the ROTEG analyzer and the thrombin generation assay.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients

NCT01228058

Coagulopathy

COMPLETED

Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle

NCT00178542

Von Willebrand Disease

TERMINATED

Thromboelastography (TEG®) and Platelet Function in Patients on Anti-platelet Agents

NCT00901160

Blood Clotting

TERMINATED

Evaluating URMC's Massive Transfusion Protocol

NCT02083549

Blood Coagulation Disorders Trauma Acute Coagulopathy

COMPLETED

Thrombin Generation in Liver Transplant Surgery

NCT04762550

Liver Transplantation Thrombin Hemostasis, Surgical +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an exploratory study involving blood coagulation assays in a select group of individuals receiving treatment for their congenital or acquired bleeding or clotting disorder at UTHealth Houston. The ROTEG is a newly developed coagulation analyzer which allows the continuous assessment of whole blood coagulation from the formation of the first fibrin fibers and activated platelets, to the formation of a three-dimensional whole blood clot until the eventual dissolution of the clot. This device will not be used as a diagnostic or procedure tool. No recommendations regarding interpretation of the results or implications for future treatment will be provided.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Coagulation Disorders, Inherited Thrombotic Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria: patients with congenital or acquired bleeding or clotting disorders who have provided informed consent and/or assent

Exclusion Criteria: poor venous access

Minimum Eligible Age

1 Day

Maximum Eligible Age

98 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No